Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Globe Newswire•10/08/2026•16:05 ET
0
Whiz Insights
Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A
$120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027
Get started
Create a free account to read the full story.